Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H12FN3O3 |
Molecular Weight | 313.2832 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C2=CC=C(C=C2C(=NCC1=O)C3=CC=CC=C3F)[N+]([O-])=O
InChI
InChIKey=PPTYJKAXVCCBDU-UHFFFAOYSA-N
InChI=1S/C16H12FN3O3/c1-19-14-7-6-10(20(22)23)8-12(14)16(18-9-15(19)21)11-4-2-3-5-13(11)17/h2-8H,9H2,1H3
Molecular Formula | C16H12FN3O3 |
Molecular Weight | 313.2832 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
http://en.pharmacodia.com/yaodu/html/v1/chemicals/f0782c53cab465685c663c70eb6d85e5.html | https://www.drugs.com/illicit/rohypnol.html
Curator's Comment: description was created based on several sources, including:
http://en.pharmacodia.com/yaodu/html/v1/chemicals/f0782c53cab465685c663c70eb6d85e5.html | https://www.drugs.com/illicit/rohypnol.html
Flunitrazepam is an intermediate-acting benzodiazepine with general properties similar to those of diazepam. It is generally intended to be for short-term treatment for chronic or severe insomniacs who are unresponsive to other hypnotics. The main pharmacological effects of Flunitrazepam are the enhancement of GABA at the GABAA receptor. The physical effects of Flunitrazepam include sedation, muscle relaxation, decreased anxiety, and prevention of convulsions. It causes partial amnesia; individuals are unable to remember certain events that they experience while under the influence of the drug. Chronic use of Flunitrazepam can result in physical dependence and the appearance of a withdrawal syndrome when the drug is discontinued. Flunitrazepam impairs cognitive and psychomotor functions affecting reaction time and driving skill. The use of this drug in combination with alcohol is a particular concern as both central nervous system depressants potentiate each other's toxicity.
CNS Activity
Originator
Sources: https://www.google.com/patents/US3116203
Curator's Comment: # Hoffmann La Roche
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093872 |
|||
Target ID: CHEMBL2095172 Sources: DOI: 10.1111/j.1440-1681.2008.04946.x |
0.45 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Rohypnol Approved UseRohypnol is generally intended to be for short-term treatment for chronic or severe insomniacs who are unresponsive to other hypnotics. Launch Date1982 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
21.7 ng/mL |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUNITRAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
10.2 ng/mL |
2 mg 1 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FLUNITRAZEPAM blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
12.2 ng/mL |
2 mg 1 times / day steady-state, oral dose: 2 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FLUNITRAZEPAM blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
12.9 ng/mL |
2 mg 1 times / day steady-state, oral dose: 2 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FLUNITRAZEPAM blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
47.5 ng/mL |
2 mg single, intravenous dose: 2 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
FLUNITRAZEPAM blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
11.5 ng/mL |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUNITRAZEPAM blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
25 ng/mL |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUNITRAZEPAM blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
12.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2096104/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUNITRAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
13.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2096104/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUNITRAZEPAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
9.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2096104/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUNITRAZEPAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
203 ng × h/mL |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUNITRAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
232.8 ng × h/mL |
2 mg single, intravenous dose: 2 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
FLUNITRAZEPAM blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
116.7 ng × h/mL |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUNITRAZEPAM blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
240.2 ng × h/mL |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUNITRAZEPAM blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
21.2 h |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUNITRAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
24 h |
2 mg single, intravenous dose: 2 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
FLUNITRAZEPAM blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
6.8 h |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUNITRAZEPAM blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
6.2 h |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUNITRAZEPAM blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
22.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2096104/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUNITRAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
25.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2096104/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUNITRAZEPAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
20.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2096104/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUNITRAZEPAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20.4% |
FLUNITRAZEPAM plasma | Homo sapiens |
Doses
Dose | Population | Adverse events |
---|---|---|
8 mg 1 times / day multiple, oral Highest studied dose Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
Other AEs: Drowsiness, Hypotonia... |
1.3 mg/kg single, intravenous Highest studied dose Dose: 1.3 mg/kg Route: intravenous Route: single Dose: 1.3 mg/kg Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Other AEs: Respiratory depression... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Drowsiness | 8 mg 1 times / day multiple, oral Highest studied dose Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
|
Hypotonia | 8 mg 1 times / day multiple, oral Highest studied dose Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
|
Respiratory depression | 1.3 mg/kg single, intravenous Highest studied dose Dose: 1.3 mg/kg Route: intravenous Route: single Dose: 1.3 mg/kg Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major [Km 155 uM] | ||||
minor [Km 101 uM] | ||||
minor [Km 1921 uM] | ||||
minor [Km 50 uM] | ||||
minor [Km 60 uM] | ||||
no | ||||
unlikely | ||||
unlikely | ||||
unlikely | ||||
unlikely |
PubMed
Title | Date | PubMed |
---|---|---|
Synergistic protection of allopregnanolone and phenobarbital against maximal electroshock seizures in mice. | 2001 Apr |
|
Semiautomated high-performance liquid chromatographic method for the determination of benzodiazepines in whole blood. | 2001 Apr |
|
High-performance liquid chromatography determination of flunitrazepam and its metabolites in plasma by use of column-switching technique: comparison of two extraction columns. | 2001 Apr 25 |
|
[Clonidine combined with flunitrazepam before carotid endarterectomy decreases cerebrovascular CO2 reactivity]. | 2001 Aug |
|
Flunitrazepam abuse and personality characteristics in male forensic psychiatric patients. | 2001 Aug 5 |
|
Losigamone. Dr Willmar Schwabe. | 2001 Dec |
|
Density and distribution of hippocampal neurotransmitter receptors in autism: an autoradiographic study. | 2001 Dec |
|
Mercury interaction with the GABA(A) receptor modulates the benzodiazepine binding site in primary cultures of mouse cerebellar granule cells. | 2001 Dec |
|
Simultaneous determination of fifteen low-dosed benzodiazepines in human urine by solid-phase extraction and gas chromatography-mass spectrometry. | 2001 Dec 25 |
|
Binding of [3H]CB 34, a selective ligand for peripheral benzodiazepine receptors, to rat brain membranes. | 2001 Dec 7 |
|
Activation of GABA(A) receptors in subthalamic neurons in vitro: properties of native receptors and inhibition mechanisms. | 2001 Jul |
|
Drug-facilitated date rape. | 2001 Jul 10 |
|
Olanzapine-induced retarded ejaculation: role of paroxetine comedication? A case report. | 2001 Jul-Aug |
|
Atrial flutter in fetuses and early childhood: a report of eight cases. | 2001 Jun |
|
Drug-facilitated sexual assault. | 2001 Jun |
|
Patient information. Date rape drugs: what parents should know. | 2001 Jun |
|
Differential sensitivity to the anxiolytic effects of ethanol and flunitrazepam in PKCgamma null mutant mice. | 2001 May-Jun |
|
Pharmacodynamic and receptor binding changes during chronic lorazepam administration. | 2001 May-Jun |
|
Influence of membrane cholesterol on modulation of the GABA(A) receptor by neuroactive steroids and other potentiators. | 2001 Nov |
|
Flunitrazepam: an evaluation of use, abuse and toxicity. | 2001 Nov 1 |
|
Modulation of rate of onset and intensity of drug effects reduces abuse potential in healthy males. | 2001 Nov 1 |
|
Determination of benzodiazepines in human hair by on-line high-performance liquid chromatography using a restricted access extraction column. | 2001 Nov 15 |
|
Evidence for the formation of functionally distinct alphabetagammaepsilon GABA(A) receptors. | 2001 Nov 15 |
|
Characterization of [3H]flunitrazepam binding to melanin. | 2001 Nov 15 |
|
3Alpha-hydroxy-5alpha-pregnan-20-one levels and GABA(A) receptor-mediated 36Cl(-) flux across development in rat cerebral cortex. | 2001 Nov 26 |
|
Serum and urine concentrations of flunitrazepam and metabolites, after a single oral dose, by immunoassay and GC-MS. | 2001 Nov-Dec |
|
[Tetraplegia in the course of coma from drug intoxication]. | 2001 Oct |
|
[Clinical aspects of abuse drugs mainly used by adolescents]. | 2001 Oct |
|
Pressure-sensitive and -insensitive coupling in gamma-aminobutyric acid(A) receptors. | 2001 Oct |
|
3H-nicotine, 3H-flunitrazepam, and 3H-cocaine incorporation into melanin: a model for the examination of drug-melanin interactions. | 2001 Oct |
|
Mutagenesis of the GABA(A) receptor alpha1 subunit reveals a domain that affects sensitivity to GABA and benzodiazepine-site ligands. | 2001 Oct |
|
Evidence for a role for GABA(A) and NMDA receptors in ethanol inhibition of long-term potentiation. | 2001 Oct 19 |
|
Deposition of 7-aminoflunitrazepam and flunitrazepam in hair after a single dose of Rohypnol. | 2001 Sep |
|
Lack of allosteric modulation of striatal GABA(A) receptor binding and function after cocaine sensitization. | 2001 Sep |
|
Distinct signal transduction pathways for GABA-induced GABA(A) receptor down-regulation and uncoupling in neuronal culture: a role for voltage-gated calcium channels. | 2001 Sep |
|
Sensitive method for the detection of 22 benzodiazepines by gas chromatography-ion trap tandem mass spectrometry. | 2002 Apr 19 |
|
[Clonidine vs. Midazolam for premedication - comparison of the anxiolytic effect by using the STAI-test]. | 2002 Feb |
|
Mechanism of alpha-subunit selectivity of benzodiazepine pharmacology at gamma-aminobutyric acid type A receptors. | 2002 Feb 15 |
|
Modulation of radioligand binding to the GABA(A)-benzodiazepine receptor complex by a new component from Cyperus rotundus. | 2002 Jan |
|
Role of the histidine residue at position 105 in the human alpha 5 containing GABA(A) receptor on the affinity and efficacy of benzodiazepine site ligands. | 2002 Jan |
|
Gamma-aminobutyric acidA and benzodiazepine receptor alterations in the rat brain after unilateral 6-hydroxydopamine lesions of the medial forebrain bundle. | 2002 Jan |
|
Buprenorphine prescription by general practitioners in a French region. | 2002 Jan 1 |
|
Binding and neuropharmacological profile of zaleplon, a novel nonbenzodiazepine sedative/hypnotic. | 2002 Jan 2 |
|
Psychological stress, but not physical stress, causes increase in diazepam binding inhibitor (DBI) mRNA expression in mouse brains. | 2002 Jul 15 |
|
Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate. | 2002 Jun 1 |
|
Coordinate release of ATP and GABA at in vitro synapses of lateral hypothalamic neurons. | 2002 Jun 15 |
|
Simultaneous analysis of flunitrazepam and its major metabolites in human plasma by high performance liquid chromatography tandem mass spectrometry. | 2002 Jun 15 |
|
Drugged and sexually assaulted. | 2002 Mar |
|
Plasticity of GABA(a) system during ageing: focus on vestibular compensation and possible pharmacological intervention. | 2002 Mar 1 |
|
Citalopram in fatal poisoning cases. | 2002 Mar 28 |
Patents
Sample Use Guides
Usual dose 0.5 - 1mg; in exceptional circumstances the dose may be increased to 2mg.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17976880
The binding affinity for [3H]flunitrazepam was most affected in the hippocampus where there was a significant drug ×time interaction (F4,49= 4.6, p<0.01).
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:46:03 GMT 2025
by
admin
on
Mon Mar 31 17:46:03 GMT 2025
|
Record UNII |
620X0222FQ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN05CD03
Created by
admin on Mon Mar 31 17:46:03 GMT 2025 , Edited by admin on Mon Mar 31 17:46:03 GMT 2025
|
||
|
DEA NO. |
2763
Created by
admin on Mon Mar 31 17:46:03 GMT 2025 , Edited by admin on Mon Mar 31 17:46:03 GMT 2025
|
||
|
NCI_THESAURUS |
C1012
Created by
admin on Mon Mar 31 17:46:03 GMT 2025 , Edited by admin on Mon Mar 31 17:46:03 GMT 2025
|
||
|
WHO-ATC |
N05CD03
Created by
admin on Mon Mar 31 17:46:03 GMT 2025 , Edited by admin on Mon Mar 31 17:46:03 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
4193
Created by
admin on Mon Mar 31 17:46:03 GMT 2025 , Edited by admin on Mon Mar 31 17:46:03 GMT 2025
|
PRIMARY | |||
|
620X0222FQ
Created by
admin on Mon Mar 31 17:46:03 GMT 2025 , Edited by admin on Mon Mar 31 17:46:03 GMT 2025
|
PRIMARY | |||
|
m5447
Created by
admin on Mon Mar 31 17:46:03 GMT 2025 , Edited by admin on Mon Mar 31 17:46:03 GMT 2025
|
PRIMARY | Merck Index | ||
|
CHEMBL13280
Created by
admin on Mon Mar 31 17:46:03 GMT 2025 , Edited by admin on Mon Mar 31 17:46:03 GMT 2025
|
PRIMARY | |||
|
1202
Created by
admin on Mon Mar 31 17:46:03 GMT 2025 , Edited by admin on Mon Mar 31 17:46:03 GMT 2025
|
PRIMARY | |||
|
1622-62-4
Created by
admin on Mon Mar 31 17:46:03 GMT 2025 , Edited by admin on Mon Mar 31 17:46:03 GMT 2025
|
PRIMARY | |||
|
DTXSID7023065
Created by
admin on Mon Mar 31 17:46:03 GMT 2025 , Edited by admin on Mon Mar 31 17:46:03 GMT 2025
|
PRIMARY | |||
|
100000092658
Created by
admin on Mon Mar 31 17:46:03 GMT 2025 , Edited by admin on Mon Mar 31 17:46:03 GMT 2025
|
PRIMARY | |||
|
31622
Created by
admin on Mon Mar 31 17:46:03 GMT 2025 , Edited by admin on Mon Mar 31 17:46:03 GMT 2025
|
PRIMARY | |||
|
6960
Created by
admin on Mon Mar 31 17:46:03 GMT 2025 , Edited by admin on Mon Mar 31 17:46:03 GMT 2025
|
PRIMARY | |||
|
3380
Created by
admin on Mon Mar 31 17:46:03 GMT 2025 , Edited by admin on Mon Mar 31 17:46:03 GMT 2025
|
PRIMARY | |||
|
4460
Created by
admin on Mon Mar 31 17:46:03 GMT 2025 , Edited by admin on Mon Mar 31 17:46:03 GMT 2025
|
PRIMARY | RxNorm | ||
|
FLUNITRAZEPAM
Created by
admin on Mon Mar 31 17:46:03 GMT 2025 , Edited by admin on Mon Mar 31 17:46:03 GMT 2025
|
PRIMARY | |||
|
2951
Created by
admin on Mon Mar 31 17:46:03 GMT 2025 , Edited by admin on Mon Mar 31 17:46:03 GMT 2025
|
PRIMARY | |||
|
DB01544
Created by
admin on Mon Mar 31 17:46:03 GMT 2025 , Edited by admin on Mon Mar 31 17:46:03 GMT 2025
|
PRIMARY | |||
|
D005445
Created by
admin on Mon Mar 31 17:46:03 GMT 2025 , Edited by admin on Mon Mar 31 17:46:03 GMT 2025
|
PRIMARY | |||
|
C87672
Created by
admin on Mon Mar 31 17:46:03 GMT 2025 , Edited by admin on Mon Mar 31 17:46:03 GMT 2025
|
PRIMARY | |||
|
216-597-8
Created by
admin on Mon Mar 31 17:46:03 GMT 2025 , Edited by admin on Mon Mar 31 17:46:03 GMT 2025
|
PRIMARY | |||
|
SUB07710MIG
Created by
admin on Mon Mar 31 17:46:03 GMT 2025 , Edited by admin on Mon Mar 31 17:46:03 GMT 2025
|
PRIMARY | |||
|
Flunitrazepam
Created by
admin on Mon Mar 31 17:46:03 GMT 2025 , Edited by admin on Mon Mar 31 17:46:03 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
LABELED -> NON-LABELED |
|
||
|
TARGET -> ACTIVATOR |
ALLOSTERIC ACTIVATOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
METABOLITE ACTIVE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE ACTIVE -> PARENT |
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|